My Account Log in

4 options

Small Molecules in Hematology / edited by Uwe M. Martens.

Online

Available online

View online
LIBRA RC261 .R35 v.1 (1965)-v.5 (1966), v.7 (1966)-v.98 (1985), v.100 (1986)-v.121 (1991), v.123 (1991)-v.126 (1993), v.128 (1993)-v.158 (2000); v.13:2nd ed. (1976) 1969
Loading location information...

Available from offsite location This item is stored in our repository but can be checked out.

Log in to request item
Holman Biotech Commons - Periodicals Per. v.159 (2002)-184,186,188-189,191-192,194-196
Loading location information...

Mixed Availability Some items are available, others may be requested.

Log in to request item
Levy Dental Medicine Library - Stacks RC261 .R35 149
Loading location information...

Mixed Availability Some items are available, others may be requested.

Log in to request item
Format:
Book
Contributor:
Martens, Uwe M., editor.
SpringerLink (Online service)
Series:
Recent results in cancer research 0080-0015 ; 212.
Recent Results in Cancer Research, 0080-0015 ; 212
Language:
English
Subjects (All):
Medicine.
Hematology.
Oncology.
Medicine & Public Health.
Local Subjects:
Medicine & Public Health.
Hematology.
Oncology.
Physical Description:
1 online resource (VIII, 294 pages) : 28 illustrations, 17 illustrations in color.
Edition:
Third edition 2018.
Contained In:
Springer eBooks
Place of Publication:
Cham : Springer International Publishing : Imprint: Springer, 2018.
System Details:
text file PDF
Summary:
This book, written by respected experts, discusses in detail the latest developments in targeted therapy for hematologic malignancies using small molecules. It covers a wide range of small molecules including tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor venetoclax, and the proteasome inhibitor carfilzomib. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed. Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of precision cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. An accompanying volume addresses the use of small molecules in oncology, and the two volumes together represent the third edition of the book originally published under the same title. .
Contents:
Imatinib
Dasatinib
Nilotinib
Bosutinib
Ponatinib
Ruxolitinib
Ibrutinib
Lenalidomide
Pomalidomide
Enasidenib
Midostaurin
Alectinib
Osimertinib
Venetoclax
Idelaslisib
Carfilzomib
Acalabrutinib.
Other Format:
Printed edition:
ISBN:
9783319914398
Access Restriction:
Restricted for use by site license.

The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.

Find

Home Release notes

My Account

Shelf Request an item Bookmarks Fines and fees Settings

Guides

Using the Find catalog Using Articles+ Using your account